Market capitalization | SEK17.85b |
Enterprise Value | SEK17.11b |
P/E (TTM) P/E ratio | 19.49 |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 11.28 |
P/S ratio (TTM) P/S ratio | 11.76 |
P/B ratio (TTM) P/B ratio | 9.08 |
Revenue growth (TTM) Revenue growth | 501.61% |
Revenue (TTM) Revenue | SEK1.52b |
As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.
5 Analysts have issued a BioArctic AB forecast:
5 Analysts have issued a BioArctic AB forecast:
Mar '25 |
+/-
%
|
||
Revenue | 1,517 1,517 |
502%
502%
|
|
Gross Profit | 1,481 1,481 |
604%
604%
|
|
EBITDA | 923 923 |
-
|
EBIT (Operating Income) EBIT | 920 920 |
860%
860%
|
Net Profit | 902 902 |
838%
838%
|
In millions SEK.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BioArctic AB engages in the research and development of modifying treatments and diagnostics for neurodegenerative diseases. Its research areas are Alzheimer’s disease and Parkinson’s disease where there are large unmet medical needs. The company was founded by Lars Gunnar Lannfelt and Pär Lars Gellerfors on January 24, 2003 and is headquartered in Stockholm, Sweden.
Head office | Sweden |
CEO | Gunilla Osswald |
Employees | 107 |
Founded | 2000 |
Website | www.bioarctic.se |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.